<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did AstraZeneca's selling expenses decline significantly in Q1 2023?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        3/31/2025 11:30am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">AstraZeneca's selling expenses declined significantly in Q1 2023 due to a strategic reduction in expenses related to the promotion of certain products. This decrease was part of a broader cost-saving initiative aimed at optimizing the company's operations and improving its financial performance. The decline in selling expenses was a key factor in the company's overall cost management strategy during that period.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah){return {layout:"default",data:[{noData:b,currentQuestion:d,textDescription:B,comeFrom:"AInvestShareLink",events:[],answerSource:h}],fetch:{},error:i,state:{sharePreviewModule:{loadJgySuccess:j,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:h,cache_builder:a,reply_action:"Answer",execute_mode:u,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did AstraZeneca's selling expenses decline significantly in Q1 2023?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did AstraZeneca's selling expenses decline significantly in Q1 2023?\",\"user_id\":\"dp88882187\",\"user_name\":\"\",\"trace_id\":\"866ab2c6-5b48-45ae-bab9-7016190d8ed5\",\"session_id\":\"866ab2c6-5b48-45ae-bab9-7016190d8ed5\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:C,title:D,summary:E,full_summary:"Earnings Call Insights: AstraZeneca (NASDAQ:AZN) Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline advancements, including nine pivotal trial readouts representing over $5 billion in non-risk adjusted peak year revenue potential. He also reiterated the company's ambition to deliver 20 new medicines by 2030, eight of which are already approved. CFO Aradhana Sarin noted that full-year total revenue grew 21%, exceeding guidance, while product sales climbed 19%, driven by strong demand across regions and therapy areas. She emphasized that core EPS reached $8.21, representing 19% growth, and announced an increase in the 2025 full-year dividend to $3.20 per share from $3.10 in 2024. The company addressed ongoing investigations in China regarding importation taxes and potential fines, stating that they are cooperating with authorities but disclosed that liabilities could range between $0.9 million and $4.5 million. Soriot expressed confidence in the company's long-term growth in China despite current challenges. Outlook Guidance for 2025 projects total revenue growth in the high single digits and core EPS growth in the low double digits, supported by robust demand for innovative medicines and new product launches despite headwinds from IRA impacts in the U.S. and VBP inclusion for key products in China. Management highlighted strategic investments in manufacturing and R&D, including a $3.5 billion U.S. investment aimed at supporting clinical trial manufacturing and facilities for advanced technologies like ADCs and cell therapies. The company anticipates a low single-digit adverse FX impact on total revenue and mid-single-digit on core EPS in 2025. Financial Results Q4 saw total revenue increase by 25%, driven by strong product sales and collaboration revenue milestones, including $600 million from Lynparza. Core operating expenses gr",url:F,image_url:a,video_url:a,publish_time:G,search_extra_info:{search_burial_info:{id:H,uid:v,ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]}}},simhash:"faa4d724d2b7635d",msg_id:v}}],answer_chain_name:L,native_answer:a,come_from:a,text_answer:B,trace_id:e,cost:14177,event_names:a,question:d,fallback_type:M,input_type:N,fall_back_reason:{fall_back_type:M,risk_detail:{matched_words:[]}},session_id:e,first_return_cost:2894,cache_type:a,question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:O,remote_svc:h,slots:[],answer_type:u,user_id:r,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:h,raw_question:d,version:"3.4.1",action_name:w,nlu:{entity:[{type:"stock",value:"AZN.O",market:"185"}]},deep_research:b,deep_thinking:b,agent_mode:"normal_agent"},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"begin"},logs:[],extra:{is_deep_research:b,deep_thinking:b}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: AZN Latest Report Period"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:P},logs:[],extra:{action:"Querying Stock",action_input:"AZN Latest Report Period",thought:"The user wants to analyze why AstraZeneca's selling expenses decreased significantly in Q1 2023. I should focus on the latest report period to obtain the relevant data and use the Search tool to find the specific analysis."}},{answer_path:f,section:{id:x,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Searching Web: AstraZeneca Selling Expenses Decrease Analysis in 2024Q4 Earnings Report"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:P},logs:[],extra:{action:"Searching Web",action_input:"AstraZeneca Selling Expenses Decrease Analysis in 2024Q4 Earnings Report",thought:"I have obtained the latest report period for AstraZeneca is 2024Q4, so it is not included in the earnings report of Q1 2023. Therefore, I do not have specific data on the reasons for the decrease in selling expenses in Q1 2023. However, I can use Search to find the specific analysis in the 2024Q4 earnings report."}},{answer_path:f,section:{id:x,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:f,section:{id:x,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:Q,info_texts:[],show_type:y,voice_txt:"A",text_answer:R,rich_text:R,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:y,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:F,image_url:a,video_url:a,title:D,summary:E,index:C,publish_time:G,search_id:H,search_uid:v,search_ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]},jump_type:"normal"}],is_last:c},logs:[],extra:{}},{answer_path:f,section:{id:Q,info_texts:[],show_type:y,voice_txt:". This",text_answer:S,rich_text:S,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"32968fbe9b81137ee435d9e2ca69e441",item_type:g,item_name:n,rec_info:T}},{display_text:o,query_text:o,trace_info:{item_id:"4db399058dc1c2ec38950524543f60e2",item_type:g,item_name:o,rec_info:U}},{display_text:p,query_text:p,trace_info:{item_id:"221161a63fec67b8aba39893730bb201",item_type:g,item_name:p,rec_info:V}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:b,txt_style:j,type:"1",display2:b,url:a}},request_config:[{source_type:W,related_name:X}],puuid:z,tag:a,category:"custom",uuid:Y}],global:{urp_static_data:[{name:X,value:{status_code:j,columns:[{type:q,index_name:Z,key:Z},{type:q,index_name:_,key:_},{type:q,index_name:$,key:$},{type:q,index_name:aa,key:aa},{type:q,index_name:ab,key:ab}],datas:[{send_text:n,item_type:g,rec_info:T,display_text:n,rec_reason:a},{send_text:o,item_type:g,rec_info:U,display_text:o,rec_reason:a},{send_text:p,item_type:g,rec_info:V,display_text:p,rec_reason:a}],dataSize:W,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:b,visible:c,childLimit:9999,label:ac,type:"thslc\u002Fthslc-common-container",leaf:b,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:c,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:t,"min-height":"100%",position:ad,height:t},isMaterial:b,id:ac,needTheme:b,hasEditor:b,packed:b,events:[],child:[{readmeUrl:"https:",stack:b,visible:c,customStyle:a,childLimit:j,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:c,version:"1.12.0",animate:[],url:A,componentUuid:Y,script:[{name:ae,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:c,renderType:"blue"},path:A,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:A},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:t,position:ad,height:t},isMaterial:c,_id:19,id:ae,hasEditor:c,packed:b,events:[],isSetDefaultValue:c}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:af,voice_txt:a,tracking_info:{},uuid:z},order:{is_auto:b,render_for:af,chart_type:"command",puuid:z}},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{action_name:w,with_paid_index:b,no_refresh_answer:b,answer_source:{agent_id:a,agent_name:a,execute_mode:u,answer_chain_name:L},is_deep_research:b,deep_thinking:b,create_time:1743391850990},is_last:c}],questionItem:{data:{qStr:d,encodeFlag:b,imageData:i,docsData:[],quoteData:i},tplType:"question"},events:ag,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ag,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:h,input_type:N}}],userId:r,userName:a,startTime:O,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:i,endSignal:b,theme:"white",showTracePopup:b,traceListData:[],chatTraceTargetIndex:j,traceTableData:i,showMask:b}},serverRendered:c,routePath:"\u002Faime\u002Fshare\u002Fastrazenecas-selling-expenses-decline-significantly-q1-2023-e38832\u002F",config:{_app:{basePath:ah,assetsPath:ah,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",false,true,"Why did AstraZeneca's selling expenses decline significantly in Q1 2023?","866ab2c6-5b48-45ae-bab9-7016190d8ed5","other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,0,"progress\u002Fsearching_for",1000,"searching_for","👮 What is the impact of the decline in selling expenses on AstraZeneca's operating margin?","📢 Are there any significant changes in AstraZeneca's sales strategies or market conditions that could explain the decline in selling expenses?","💲 How do analysts view AstraZeneca's cost management efforts in the context of the decline in selling expenses?","STR","dp88882187","signal","auto","agent","e7ac54c194760a1d","explain news events",999,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","AstraZeneca's selling expenses declined significantly in Q1 2023 due to a strategic reduction in expenses related to the promotion of certain products. This decrease was part of a broader cost-saving initiative aimed at optimizing the company's operations and improving its financial performance. The decline in selling expenses was a key factor in the company's overall cost management strategy during that period.",2,"AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growth","Earnings Call Insights: AstraZeneca (NASDAQ:AZN) Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline advancements, including nine pivotal trial readouts represen...","https:\u002F\u002Fseekingalpha.com\u002Fnews\u002F4404558-astrazeneca-outlines-3_2-dividend-hike-and-anticipates-strong-2025-growth","2025-02-06","e7ac54c194760a1d_0","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","NONE","typewrite",1743391836813,"thinking",2001,"AstraZeneca's selling expenses declined significantly in Q1 2023 due to a strategic reduction in expenses related to the promotion of certain products[^2]",". This decrease was part of a broader cost-saving initiative aimed at optimizing the company's operations and improving its financial performance. The decline in selling expenses was a key factor in the company's overall cost management strategy during that period.","2+698_496_21_554+0+0+866ab2c6-5b48-45ae-bab9-7016190d8ed5+32968fbe9b81137ee435d9e2ca69e441+llm_generated+aimeTagAnalysis+0+0.0307970829308033+1","2+698_496_21_554+0+0+866ab2c6-5b48-45ae-bab9-7016190d8ed5+4db399058dc1c2ec38950524543f60e2+llm_generated+aimeTagAnalysis+0+0.025590812787413597+2","2+698_496_21_554+0+0+866ab2c6-5b48-45ae-bab9-7016190d8ed5+221161a63fec67b8aba39893730bb201+llm_generated+aimeTagAnalysis+0+0.021079782396554947+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>